Devanand C Sarkar

US Patent:

20050287120, Dec 29, 2005

Filed:

Jan 11, 2005

Appl. No.:

11/032757

Inventors:

Paul Fisher - Scarsdale NY, US
Devanand Sarkar - Elmsford NY, US

International Classification:

A61K048/00
C12N007/00
C12N015/861

US Classification:

424093200, 435456000, 435235100

Abstract:

The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased replication in malignant cells, thereby producing a cytopathic effect. The viral vectors of the invention may comprise additional genes of interest, and/or may have altered capsid proteins that may enhance infection of and/or target infection to cancer cells. Additional cell types derived from diseased states in which the PEG-3 promoter is selectively active are also therapeutic targets of the viral vectors of the instant invention including those generating allergic, autoimmune and inflammatory responses.

US Patent:

20060140959, Jun 29, 2006

Filed:

Jul 21, 2005

Appl. No.:

11/186718

Inventors:

Paul Fisher - Scarsdale NY, US
Magdalena Leszczyniecka - Cambridge MA, US
Dong-Chul Kang - Anyang, KR
Devanand Sarkar - Elmsford NY, US

International Classification:

A61K 39/395
C12Q 1/68
C07H 21/04
C12P 21/06
C07K 14/82
C07K 16/30

US Classification:

424155100, 435006000, 435069100, 435320100, 435325000, 530350000, 530388800, 536023500

Abstract:

The present invention relates to the old-35 gene, its encoded protein, and its promoter sequence. The old-35 gene is associated with terminal differentiation and senescence of cells, and as such the gene and its related molecules may be used in the control of cell proliferation and in the modulation

US Patent:

20080057055, Mar 6, 2008

Filed:

Apr 5, 2007

Appl. No.:

11/784096

Inventors:

Paul Fisher - Scarsdale NY, US
Devanand Sarkar - Elmsford NY, US

International Classification:

A61K 39/395
A01K 67/033
A61P 19/02
C07H 21/00
G01N 33/50
C12Q 1/68
A61P 25/28
A61K 31/7088

US Classification:

424130100, 435006000, 436094000, 514044000, 536023100, 800012000, 800009000

Abstract:

The present invention relates to the discovery that OLD-35, at least in part through the generation of reactive oxygen species, induces a number of inflammatory cytokines and promotes nuclear translocation and binding of the transcriptional activator NF-κB. Accordingly, the present invention provides for assay systems (which either utilize the old-35 promoter or the old-35 gene) that may be used to identify new anti-inflammatory agents; model systems of inflammation based on over-expression of the old-35 gene in cells and tissues (including specific model systems for arthritis, atherosclerosis and Alzheimer's disease); methods and kits for diagnosing old-35 associated inflammatory conditions, and methods of treatment and anti-inflammatory compositions that utilize agents that antagonize OLD-35 activity.

US Patent:

20080213220, Sep 4, 2008

Filed:

Jul 11, 2007

Appl. No.:

11/827388

Inventors:

Paul B. Fisher - Richmond VA, US
Devanand Sarkar - Richmond VA, US

International Classification:

A61K 48/00
C12N 15/861
A61P 35/00

US Classification:

424 932, 435456, 4353201

Abstract:

The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased replication in malignant cells, thereby producing a cytopathic effect. The viral vectors of the invention further comprise additional genes of interest, and/or may have altered capsid proteins that may enhance infection of and/or target infection to cancer cells. Additional cell types derived from diseased states in which the PEG-3 promoter is selectively active are also therapeutic targets of the viral vectors of the instant invention including those generating allergic, autoimmune and inflammatory responses.

US Patent:

20110313028, Dec 22, 2011

Filed:

Nov 25, 2009

Appl. No.:

13/130745

Inventors:

Paul B. Fisher - Richmond VA, US
Devanand Sarkar - Richmond VA, US

Assignee:

VIRGINIA COMMONWEALTH UNIVERSITY - Richmond VA

International Classification:

A61K 48/00
A61P 35/00
C12N 15/85
C12N 5/10
C07H 21/04
C12N 15/63

US Classification:

514 44 R, 536 235, 4353201, 435455, 435325

Abstract:

Methods, compositions, and therapeutic products for use in the field of oncology and specifically, for the treatment of cancer and other diseases in which SARI is ameliorative or therapeutic and/or small molecule screening for anti-cancer drugs are provided. Cancer specific gene expression using the CCN1 promoter, which is negatively regulated by SARI, for targeting therapeutic molecules in tumors is also provided.

US Patent:

20120195935, Aug 2, 2012

Filed:

Jul 27, 2010

Appl. No.:

13/386165

Inventors:

Paul B. Fisher - Richmond VA, US
Devanand Sarkar - Richmond VA, US
Rupesh Dash - Richmond VA, US
Belal Mohammed Azab - Richmond VA, US
Xiang-Yang Wang - Richmond VA, US
Pier Paolo Claudio - Huntington WV, US

Assignee:

VIRGINIA COMMONWEALTH UNIVERSITY - Richmond VA

International Classification:

A61K 9/00
A61P 35/00
A61M 37/00
A61K 35/76

US Classification:

424400, 424 936, 604 22

Abstract:

Microbubble-assisted delivery of viruses is disclosed. In particular, methods for targeting a virus to cancer cells in an immunocompetent animal by administering a selectively replicating virus to the immunocompetent animal and disrupting the microbubbles in a location of the animal comprising cancer cells are provided. The virus is encompassed in a suspension of microbubbles, and the surface of the suspension does not include any virus. A suspension of microbubbles comprising a selectively replicating virus that is encompassed in a suspension of microbubbles, which does not include any virus on the surface of the suspension, is also provided.

US Patent:

20130028899, Jan 31, 2013

Filed:

Mar 29, 2011

Appl. No.:

13/636815

Inventors:

Devanand Sarkar - Richmond VA, US
Paul B. Fisher - Richmond VA, US

International Classification:

A61K 39/395
G01N 33/574
C12Q 1/68
C40B 30/04
A61K 31/7105
A61P 35/00

US Classification:

4241381, 514 44 A, 435 612, 506 9, 435 71, 435 79, 435 74

Abstract:

Inhibitors of Late SV-40 Factor (LSF) are used to treat cancers such as hepatocellular carcinoma (HCC). In particular, small molecule chemical LSF inhibitors are employed. In addition, the activity and/or pattern of expression of LSF may is used to diagnose cancer, to characterize the cancer (e.g. stage, grade, prognosis, etc.) and also to develop suitable protocols for cancer treatment.

US Patent:

20050250127, Nov 10, 2005

Filed:

Dec 22, 2004

Appl. No.:

11/019897

Inventors:

Paul Fisher - Scarsdale NY, US
Devanand Sarkar - Elmsford NY, US
Rahul Gopalkrishnan - New York NY, US
Moira Sauane - New York NY, US

International Classification:

C12Q001/68
G01N033/574

US Classification:

435006000, 435007230

Abstract:

The present invention relates to the discoveries that apoptotic effects of the melanoma differentiation associated gene mda-7 (also known as interleukin-24, “IL-24”) on malignant cells occur via the p38 MAPK pathway and members of the Growth Arrest and DNA Damage (“GADD”) gene family but are substantially independent of the JAK/STAT pathway. Accordingly, the invention provides for methods for identifying apoptosis-modulating agents using assay methods which determine the ability of a test agent to increase or decrease expression of constituents of the mda-7 apoptosis pathway, preferably in a JAK/STAT substantially independent manner. Such agents may be small molecules or may be fragments, variants and/or derivatives of native MDA-7.